WASHINGTON — Sen. Bernie Sanders plans to call the chief executives of the country’s largest insulin manufacturers to testify before his health committee, according to insulin maker Eli Lilly and two sources familiar with the plans. The move will keep the pressure on the companies over their prices despite the fact that they have said they plan to lower the list price of their older insulin products.
Sanders has alluded publicly to plans to hold a hearing on insulin affordability, but it was not clear that he planned to ask the executives of insulin makers to testify.
The committee is targeting next month for the hearing, two sources familiar with the plans said, though no dates have been officially announced. The sources spoke on condition of anonymity.
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.